OncoMatch/Clinical Trials/NCT06097793
KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
Is NCT06097793 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies KSD-101 for nasopharyngeal carcinoma.
Treatment: KSD-101 — The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated Nasopharyngeal Carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBER positive by in situ hybridization (ISH or FISH)
EBER-positive in tumor tissue by in situ hybridization (ISH or FISH)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor therapy
Patients receiving any anti-tumor therapy such as chemotherapy, radiotherapy, immunosuppressive therapy, etc. within 4 weeks prior to mono-collection
Lab requirements
Blood counts
neutrophils ≥ 1.0×10^9/l, hemoglobin ≥ 80g/l, platelets ≥ 50×10^9/l
Kidney function
creatinine ≤ 1.5 × uln
Liver function
alt, ast ≤ 3 × uln and total bilirubin ≤ 1.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify